Saturday, 5 September 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 20, 2026

ASX Stocks Estimated To Be Undervalued By Up To 30.4%

View original at finance.yahoo.com
ASX Stocks Estimated To Be Undervalued By Up To 30.4% As the Australian market faces a cautious opening with expectations of a 20-point drop, driven by concerns over rising U.S…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Integral Diagnostics (ASX:IDX) is estimated to be undervalued by 48.3% based on cash flows, with current price A$2.04 vs fair value estimate A$3.95

    60% confidence
  • Acrow (ASX:ACF) is estimated to be undervalued by 44.5% based on cash flows, with current price A$0.785 vs fair value estimate A$1.42

    60% confidence
  • ALS is poised for substantial financial growth

    60% confidence
  • ALS Limited's current trading price of A$23.15 is approximately 10.8% below its estimated future cash flow value of A$25.96, suggesting potential undervaluation based on cash flows

    60% confidence
  • Despite a high level of debt, ALS is actively seeking acquisitions that align with its strategic goals and return hurdles, potentially enhancing shareholder value further

    60% confidence
  • Rising U.S. bond yields are driving concerns over potential price pressures in the Australian economy

    60% confidence
  • Symal Group (ASX:SYL) is estimated to be undervalued by 48.8% based on cash flows, with current price A$2.46 vs fair value estimate A$4.80

    60% confidence
  • ALS reported strong earnings growth of 24.4% over the past year

    60% confidence
  • NRW Holdings (ASX:NWH) is estimated to be undervalued by 45.4% based on cash flows, with current price A$7.06 vs fair value estimate A$12.93

    60% confidence
  • Judo Capital Holdings (ASX:JDO) is estimated to be undervalued by 47.6% based on cash flows, with current price A$1.315 vs fair value estimate A$2.51

    60% confidence
  • Light & Wonder (ASX:LNW) is estimated to be undervalued by 40.8% based on cash flows, with current price A$113.85 vs fair value estimate A$192.44

    60% confidence
  • ReadyTech Holdings (ASX:RDY) is estimated to be undervalued by 45.3% based on cash flows, with current price A$1.365 vs fair value estimate A$2.49

    60% confidence
  • Nuix (ASX:NXL) is estimated to be undervalued by 49.6% based on cash flows, with current price A$1.295 vs fair value estimate A$2.57

    60% confidence
  • SiteMinder (ASX:SDR) is estimated to be undervalued by 49.3% based on cash flows, with current price A$2.66 vs fair value estimate A$5.25

    60% confidence
  • Elsight (ASX:ELS) is estimated to be undervalued by 48.4% based on cash flows, with current price A$5.74 vs fair value estimate A$11.13

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com